Abstract 312P
Background
Pancreatic cancer is a highly aggressive malignancy with relatively low morbidity, which is marked by insidious clinical symptoms but rapid development. The therapeutic options of PC are limited for the insensitivity of traditional chemoradiotherapies. The neoantigen-based vaccine is an emerging tumor immune therapeutic option, but limited evidence proved the efficient therapeutic response in pancreatic cancer.
Methods
Whole exome sequencing and bioinformatic analysis as well as quantitative real-time PCR of our previously established human pancreatic cancer cell line were performed to identify neoantigen candidates. The Immunogenicity of prioritized neoantigens was evaluated by analyzing the INF-γ secretion of neoantigen-induced T cell. The antitumor immunity of neoantigen-specific Cytotoxic T cells was examined by the cytotoxicity assay.
Results
The commutative analysis and quantitative real-time PCR identified 13 candidate neoantigens of our previously established human pancreatic cancer cell line PDXPC1 which was confirm as a multi-drug resistant cancer cell line. 4 of 13 candidate neoantigens can be recognized by the immune system and induced strong neoantigen-specific T cell response. The cytotoxic activities mediated by neoantigen-specific T cells significantly inhibited the growth of PDXPC1 tumor cells. Noteworthily, T cells recognized 3 of 4 neoepitopes via the presentation of dendritic cells.
Conclusions
In conclusion, the neoantigens selected by the next generation sequencing and computational algorithm can target the tumor inhibition of pancreatic cancer, which represent a new powerful approach for multidrug resistance and suggest a general strategy for personalized cancer immunotherapy in pancreatic cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Natural Science Foundation of Zhejiang Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session